Contents Link Navigation Link
ABOUT US

Targeting, Attacking, and Eradicating Cancers®

Company History

Targeting, Attacking, and Eradicating Cancers®

2017
Aug.Collaboration with the National Cancer Institute for development of combination therapy with Pexa-Vec and immune checkpoint inhibitors
markmark
2017
July.Approval by the China CFDA to commence phase 3 clinical trial for Pexa-Vec in liver cancer

may.Collaboration with Regeneron Pharmaceuticals for development of combination therapy with Pexa-Vec and immune checkpoint inhibitors
markmarkmark
2016
Dec.SillaJen is listed on KOSDAQ market in South Korea.

Jan.SillaJen announces first patient randomized in multinational Phase 3 trial for Pexa-Vec in Advanced Liver Cancer.
markmarkmark
2015
Oct.SillaJen is selected as the major developer for the Government project of “Global State-of-the-art technology development for biomedical products".
markmark
2015
Apr.SillaJen reached agreement with the US FDA on a Special Protocol Assessment (SPA) for multinational Phase 3 clinical trial of Pexa-Vec in Advanced Liver Cancer.
mark
2014
Mar.SillaJen acquires Jennerex, Inc., the global leader in oncolytic immunotherapeutics.

Jennerex was an early leader in the oncolytic virus field. Jennerex researchers showed that Pexa-Vec acts in three distinct ways to attack cancer: by infecting and killing cancer cells, by cutting off the blood supply to tumors, and by activating the body’s own immune system to fight cancer.MOA video 

Jennerex scientists were the first to show that IV infusion could be used to deliver oncolytic vaccinia to tumors. The key paper “Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans” showed that IV delivery of Pexa-Vec (JX-594) resulted in viral infection, viral replication and expression of a transgene marker protein in tumors in a dose dependent fashion, while healthy cells were not infected. https://www.ncbi.nlm.nih.gov/pubmed/21886163

Further work demonstrated that Pexa-Vec was able to infect the blood vessels associated with tumors, creating leaky blood vessels and disrupting the blood flow to tumors. Normal blood vessels were not affected.http://cancerres.aacrjournals.org/content/73/4/1265.short

Finally, the Jennerex sponsored phase 2 trial in Hepatocellular carcinoma paved the way for SillJen’s Phase 3 PHOCUS trial. In this dose-finding trial, patients received either a low dose or high dose of virus injected into liver tumors. Patients who received the high dose of virus had a significantly longer median overall survival time compared to the low dose group.https://www.nature.com/articles/nm.3089

mark
2013
May.US FDA designated Pexa-Vec as an orphan drug.
mark
2011
Jun.Jennerex initiated Pexa-Vec Phase 2b clinical trial (HEP018) for Liver Cancer.
markmark
2009
Nov.European Medicines Agency (EMA) designated Pexa-Vec as an orphan drug for Live Cancer.
markmarkmark
2008
Aug.Jennerex initiated Pexa-Vec Phase 2a clinical trial (HEP007).
mark
2007
Aug.Jennerex completed Pexa-Vec Phase 1 clinical trial (HEP001).
markmark
2006
Mar.SillaJen, Inc. was established.
markmarkmark
2003
Nov.Jennerex, Inc. (San Francisco, USA) was established.
mark